You are here: Industry Insights > HIV

News List

First Long-Acting Injectable Approved for HIV PrEP drugs.com
December 21, 2021
The U.S. Food and Drug Administration has approved the first long-acting injectable treatment for HIV preexposure prophylaxis, which is given every two months and offers an alternative to daily oral medication, the agency announced Monday.
Evofem Biosciences, Orion Biotechnology Enter OB-002 Alliance contractpharma
December 20, 2021
To evaluate Orion's CCR5 antagonist, OB-002, in Evofem's Phexxi vaginal gel with the goal of developing a Multipurpose Prevention Technology for HIV.
Black, Hispanic/Latino MSM Less Likely to Have HIV Diagnosis Drugs
December 14, 2021
Black and Hispanic/Latino men who have sex with men (MSM) are less likely than White MSM to receive an HIV diagnosis or use preexposure prophylaxis (PrEP)...
Transgender Individuals Have High HIV Burden Drugs
December 13, 2021
Transfeminine and transmasculine individuals are disproportionately burdened by HIV, according to a review published online Dec. 1 in PLOS ONE.
Stool Samples From the 1980s Hold Clues to Fighting HIV Today Drugs
December 10, 2021
What do all the microbes living rent-free in your gut have to do with disease risk? Perhaps a lot.
WHO Approves First Long-Acting Device to Shield Women From HIV Drugs
December 02, 2021
With HIV a continuing threat to women's health, the World Health Organization (WHO) has approved the first long-acting device to protect women from sexually transmitted HIV.
GSK aim for HIV cure by 2030 PharmaTimes
December 01, 2021
Following its recent approval of an injectable HIV-1 treatment from the National institute for Health and Care Excellence (NICE), GlaxoSmithKline (GSK) has high hopes in developing a cure for the virus in the future...
NICE approves first long-acting jab for HIV to replace daily pills PharmaTimes
November 22, 2021
NICE has published draft guidance recommending the first long-acting injectable treatment for HIV-1 infection in adults, offering an alternative to adults living with HIV who have to take daily antiretroviral drugs.
Biktarvy® shows high efficacy against HIV in real-world setting EuropeanPharmaceuticalReview
November 04, 2021
Gilead has announced interim results from the ongoing, multinational, observational single-arm, non-comparative real-world cohort BICSTaR study, designed to evaluate the antiviral effectiveness and safety profile of Biktarvy®...
Gilead Sciences Partners with the International AIDS Society to Champion Stigma-free HIV Care Services in Asia and Latin America prnasia
October 13, 2021
Gilead Sciences, Inc. today announced its partnership with IAS - the International AIDS Society - to expand the Me & My Healthcare Provider campaign to three locations in Asia...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 24 25 Next page